Pharmacological, pharmacokinetic, and clinical profile of sertraline hydrochloride (J ZOLOFT™)

Folia Pharmacologica Japonica

Volumn 128, Issue 6, 2006, Pages 417-424

  Harada, Yoshimitsu ^a   Kohara, Norihito ^a   Imaeda, Takayuki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; SEROTONIN 1A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ANTIDEPRESSANT AGENT;

CELL STRAIN HEK293; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HAMILTON SCALE; IC 50; KAPLAN MEIER METHOD; PHARMACODYNAMICS; REVIEW; ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; HUMAN; PANIC; RANDOMIZED CONTROLLED TRIAL; TABLET;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; PANIC DISORDER; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TABLETS;

EID: 39049189639     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.128.417     Document Type: Review

References (43)

1. Japanese source
2. Kupfer DJ. J Clin Psychiatry. 1991;52 Suppl 5:28-34.
3. Japanese source
4. American Psychiatric Association. Practice guideline for the treatment of patients with major epression 2nd ed. URL: http://www.psych.org/psych_pract/ treatg/pg/prac_guide.cfm
5. Japanese source
6. Goldstein BJ, et al. J Psychopharmacol. 1998;12 3 Suppl B: S55-87.
7. Japanese source
8. Japanese source
9. Fava M. J Clin Psychiatry. 2000;61 Suppl 2:S10-12.
10. Owens MJ, et al. Biol Psychiatry. 2001;50:345-350.
11. Koe BK, et al. J Pharmacol Exp Ther. 1983;226:686-700.
12. Sprouse J, et al. Neuropsychopharmacology. 1996;14:225-231.
13. Koe BK. J Clin Psychiatry. 1990;51 Suppl B:13-17.
14. Jenck F, et al. Eur J Pharmacol. 1993;231:223-229.
15. Hoyer D, et al. Eur J Pharmacol. 1989;171:137-139.
16. Cusack B, et al. Psychopharmacology (Berl). 1994;114:559-565.
17. Tadokoro C, et al. Psychopharmacology (Berl). 1997;130:124-130.
18. Butler J, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:585-594.
19. Japanese source
20. Kennett GA, et al. Br J Pharmacol. 1988;94:137-147.
21. Charney DS, et al. Psychopharmacology (Berl). 1987;92:14-24.
22. Kennedy AJ, et al. Psychopharmacology (Berl). 1993;113:262-268.
23. Japanese source
24. Japanese source
25. Hiemke C, et al. Pharmacol Ther. 2000;85:11-28.
26. Lane RM. Int Clin Psychopharmacol. 1996;11 Suppl 5:31-61.
27. Kamijima K, et al. Int Clin Psychopharmacol. 2006;21:1-9.
28. Kamijima K, et al. Int Clin Psychopharmacol. 2005;20:265-273.
29. Canadian Coordinating Office for Health Technology Assessment Selective reuptake inhibitors for major depression. Part 1. Evaluation of the clinical literature. 1997.
30. Thase ME, et al. J Clin Psychiatry. 1997;58:16-21.
31. Zarate CA Jr, et al. J Clin Psychiatry. 1996;57:67-71.
32. Brown WA, et al. J Clin Psychiatry. 1995;56:30-34.
33. Joffe RT, et al. J Clin Psychiatry. 1996;57:114-115.
34. Goldstein BJ, et al. J Psychopharmacol. 1998;12 3 Suppl B: S5-20.
35. Nemeroff CB, et al. Depression. 1995;3:163-169.
36. Franchini L, et al. J Clin Psychiatry. 1997;58:104-107.
37. Fava M, et al. J Clin Psychopharmacol. 2002;22:137-147.
38. Maurizo F, et al. J Affective Disorders. 2000;59:119-126.
39. Fava M, et al. J Clin Psychiatry. 2000;61:863-867.
40. Aberg WA, et al. J Clin Psychopharmacol. 2000;20:645-652.
41. Schmitt JAJ, et al. J Psychopharmacol. 2002;16:207-214.
42. Michelson D, et al. Br J Psychiatry. 2000;176:363-368.
43. Baldwin DS, et al. J Psychopharmacol. 2005;19:567-596.